NEW YORK (GenomeWeb News) – Epigenomics said today it has reached a deal with Polymedco to jointly commercialize Epigenomics' Epi proColon colorectal cancer screen in North America.
The test is currently under review by the US Food and Drug Administration, and Germany-based Epigenomics has said that approval is anticipated later this year. Upon approval, Polymedco would deploy its dedicated colorectal cancer sales force, technical support staff, administration, logistics, and other support functions to launch and market the test, Epigenomics said.
Both firms will jointly work on marketing, launch, and development strategies, and collaborate on reimbursement efforts for Epi proColon. Epigenomics will continue to be responsible for manufacturing the test, and for supporting it "from the medical and regulatory point of view, including the activities necessary to achieve inclusion in major cancer screening guidelines" after FDA approval, it said.
As part of the deal, Epigenomics and Polymedco have agreed to a combined transfer price and to share profits, subject to minimum annual sales of test kits to Polymedco.
Based in Cortlandt Manor, NY, Polymedco is the largest provider of colorectal cancer screening tests in North America, according to Epigenomics, and has more than $50 million in annual sales of cancer diagnostic products. Its customer base includes more than 1,500 laboratories.
"Polymedco's commitment to the [colorectal cancer] screening space will accelerate our commercial rollout in North America and will mean a significant time and resource advantage for Epigenomics in the launch of Epi proColon," Noel Doheny, CEO of Epigenomics' US subsidiary, said in a statement.